Mirum Pharmaceuticals, Inc.

This Phase 3 trial tests a drug called brelovitug (BJT-778) in 80 people with chronic hepatitis delta, a serious liver infection. Participants receive either brelovitug or delayed treatment to see if the drug can lower virus levels and improve liver enzyme counts. The study is re…

This study tests a new medicine called BJT-778 for people with chronic hepatitis delta, a serious liver infection. About 150 adults will either start the drug right away or wait 24 weeks before starting. The goal is to see if the drug can lower the virus level and improve liver h…

This Phase 3 trial tests whether maralixibat, an oral solution, can safely reduce severe itching (pruritus) in children and adults with rare cholestatic liver diseases. The study enrolls 90 participants aged 6 months and older who have not responded to other treatments. Over 20 w…

This study tests a medicine called volixibat to see if it can reduce severe itching in people with primary sclerosing cholangitis (PSC), a rare liver disease. About 182 participants will receive either volixibat or a placebo, and researchers will track itch scores using a daily d…

This study is a patient registry that will follow people of any age with bile acid synthesis disorders who are treated with Cholbam (cholic acid). The goal is to collect information over 10 years on how the drug performs in routine clinical care, including its safety, effectivene…